Business Wire

Bloom Energy Enters Northern European Markets with New Sales Agreement

27.4.2023 16:15:00 EEST | Business Wire | Press release

Share

Bloom Energy (NYSE:BE) has signed an agreement with Elugie to provide a total of 9.75 megawatts (MW) of power from the Bloom Energy Server® at five commercial, industrial and data center sites in Belgium. It is Bloom’s first entry to the northern Europe market. Elugie, which has its headquarters in Riga, Latvia, with offices in Mechelen, Belgium, is an energy service company in the Benelux market of Belgium, the Netherlands and Luxembourg.

Bloom’s solid-oxide fuel cell platforms, to be delivered in late 2023 and early 2024, will include Bloom’s new compatibility with Combined Heat and Power (CHP) systems. Elugie and Bloom are in discussions about deploying additional Bloom energy platforms to sites in the Netherlands and the Baltic nations, comprised of Latvia, Lithuania and Estonia. Elugie is also in discussions with Bloom about the opportunity to deploy the hydrogen-producing Bloom Electrolyzer™.

The agreement with Elugie is another major step in Bloom’s expansion into Europe, following marketing partnership agreements with Telam for Spain and Portugal announced earlier this year, and energy platform sales to Cefla and Ferrari in Italy announced in 2022. It will be the largest deployment of Bloom’s new CHP feature, which is an important energy efficiency and climate-friendly technology for industrial and commercial electricity users in Europe.

“This is a big win in support of our focus to build international business sales,” said Tim Schweikert, Senior Managing Director of International Business Development, Bloom Energy. “We look forward to Elugie’s work in Belgium and the many markets that it serves. This builds on our activities to grow sales across Europe and also in target markets in Asia.”

“Elugie is proud of developing opportunities with Bloom for a total capacity of 9.75MW in Belgium,” says Bjorn Van Haver, founder, Elugie. “This partnership will bring utility-scale clean solutions to critical customers in the country. Our objective is also to deploy Bloom’s servers in the Netherlands and the Baltics. Elugie is an experienced EPC (engineering, procurement and construction company) in delivering energy-as-a-service.”

For more information about Bloom Energy’s CHP technology visit:
https://www.bloomenergy.com/applications/energy-server-with-heat-capture/

Forward-Looking Statements
This press release contains certain forward-looking statements that are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or the negative of these words or similar terms or expressions that concern Bloom’s expectations, strategy, priorities, plans or intentions. These forward-looking statements include, but are not limited to: Bloom’s expectations regarding collaboration with Elugie and/or its customers; any expected features, such as CHP, or benefits from or the size of the collaboration with Elugie or installations in northern Europe; Bloom’s international expansion plans; and Bloom’s long-term commitment to particular regions, policies or imperatives. More information on potential risks and uncertainties that may impact Bloom’s business are set forth in Bloom’s periodic reports filed with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on February 21, 2023 as well as subsequent reports filed with or furnished to the SEC from time to time. Bloom assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

About Bloom Energy
Bloom Energy empowers businesses and communities to responsibly take charge of their energy. The company’s leading solid oxide platform for distributed generation of electricity and hydrogen is changing the future of energy. Fortune 100 companies around the world turn to Bloom Energy as a trusted partner to deliver lower carbon energy today and a net-zero future. For the latest news and announcements on Bloom Energy, visit https://newsroom.bloomenergy.com/.

For more information on Bloom Energy, visit https://www.bloomenergy.com/.

About Elugie
Since 2000, Elugie founder Bjorn Van Haver has been striving for a sustainable energy transition, for this and future generations. Elugie a pioneer in hydrogen power stations, where hydrogen is ingeniously converted into socially responsible electricity for buildings: more sustainable, smarter, more efficient, cheaper and autonomous from the grid. Elugie is renting power stations connected to the Elugie smart grid platform and green gas contracts. Elugie’s mission is to reduce costs, reduce carbon and maximize efficiency in compliance with the European Union taxonomy for sustainable activities. For more information, visit www.Elugie.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Bloom Energy Media Contact:
Virginia Citrano
press@bloomenergy.com

Bloom Energy Investor Relations:
Ed Vallejo
267.370.9717
Edward.Vallejo@bloomenergy.com

Elugie Media Contact:
Bjorn Van Haver
info@elugie.be

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release

IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye